Oncotarget

Priority Research Papers:

A novel read-through transcript JMJD7-PLA2G4B regulates head and neck squamous cell carcinoma cell proliferation and survival

Yingduan Cheng, Yi Wang, Jiong Li, Insoon Chang and Cun-Yu Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:1972-1982. https://doi.org/10.18632/oncotarget.14081

Metrics: PDF 1132 views  |   HTML 3176 views  |   ?  


Abstract

Yingduan Cheng1, Yi Wang1, Jiong Li1, Insoon Chang1 and Cun-Yu Wang1

1 The Division of Oral Biology and Medicine, School of Dentistry, UCLA, Los Angeles, California, USA

Correspondence to:

Cun-Yu Wang, email:

Keywords: head and neck squamous cell carcinoma, conjoined gene, JMJD7-PLA2G4B, cell cycle, apoptosis

Received: September 20, 2016 Accepted: December 15, 2016 Published: December 21, 2016

Abstract

Recent findings on the existence of oncogenic fusion genes in a wide array of solid tumors, including head and neck squamous cell carcinoma (HNSCC), suggests that fusion genes have become attractive targets for cancer diagnosis and treatment. In this study, we showed for the first time that a read-through fusion gene JMJD7-PLA2G4B is presented in HNSCC, splicing neighboring jumonji domain containing 7 (JMJD7) and phospholipase A2, group IVB (PLA2G4B) genes together. Ablation of JMJD7-PLA2G4B significantly inhibited proliferation of HNSCC cells by promoting G1 cell cycle arrest and increased starvation-induced cell death compared to JMJD7-only knockdown HNSCC cells. Mechanistically, we found that JMJD7-PLA2G4B modulates phosphorylation of Protein Kinase B (AKT) to promote HNSCC cell survival. Moreover, JMJD7-PLA2G4B also regulated an E3 ligase S-phase kinase-associated protein 2 (SKP2) to control the cell cycle progression from G1 phase to S phase by inhibiting Cyclin-dependent kinase inhibitor 1 (p21) and 1B (p27) expression. Our study provides novel insights into the oncogenic control of JMJD7-PLA2G4B in HNSCC cell proliferation and survival, and suggests that JMJD7-PLA2G4B may serve as an important therapeutic target and prognostic marker for HNSCC development and progression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14081